Innovation in Neuroscience: From Research to Business
So welcome everybody to our last this year webinar on innovation neuroscience, and my name is Dovile Kurmanaviciute. I'm an innovation agent and doctor candidate at Aalto University and I'm a part of organisers for this webinars. And today's topic is "From Research to Business", same name as Business Finland funding call. For this reason, we also have Helsinki Innovation services today with us, thanks Kajsa for joining! In this webinar we aim to show you examples and share experience on the innovation path from lab research to market. And without further do I briefly introduce our first speaker, researcher and
innovator Timo Myöhänen. Timo is group leader in NeuroPREP project at the University of Helsinki. He holds a title of docent at division of faculty of Pharmacy. Timo is also assistant professor at faculty of Pharmacy, senior research at division of Pharmacology and Pharmacotherapy, principal investigator at Regenerative Pharmacology group and also supervisor for doctor program in drug research. Welcome Timo and now screen is yours! Okay, thank you very much for the introduction and invitation for this Innovation in Neuroscience seminar. So I'm gonna present a little bit about
our NeuroPREP project. As you can see this NeuroPREP has very ambitious aims. It's about stopping the Alzheimer's and Parkinson's disease and I'm gonna introduce you a little bit how we aim to get here. And as maybe many of you know, neurodegenerative diseases are quite a lot set of diseases. Parkinson's disease has approximately 10 million patients worldwide. Alzheimer's then again way bigger with 50 million patients and common for all of these is that there is a neuron degeneration in some part of the brain causing clinical symptoms that then can be movement disorders or dementia. And another common thing for this is that
there is no curative treatment for neurodegenerative diseases. So, current treatments they can only relieve the symptoms but they cannot really block or even delay the neural degeneration that then continues all the time in the brain causing all time more severe symptoms. And what's important is that this amount of these diseases, amount of the patients with these diseases is basically constantly increasing. In the western countries the aging has been already slightly flattened but then again, there are these former third world countries, like China, where the aging is has already has started to increase. And we have to remember that the age is the most
significant risk factor for these diseases. So basically, aging increases the risk and, therefore, when there's more age people, there will be more cases with the neurodegenerative diseases. And since, we are speaking about the Business Finland project, we always need to remember a little bit of market, and it's also an increasing market. Already, with
the current therapies, that are not curative, the market is estimated to be 9 billion USD. And it's gonna, it's been estimated, that it elevates to 12 billion US dollars in 2024. So it's clear that we are in the need of new treatments that would be able to at least reduce the disease progression, or even block them, which would be of course the optimal situation. And our approach has been PREP, really little peptides, but let's just say it as a PREP and it's a serine protease. It cleaves out peptides. And back in the old days, they noticed that there is is changes in PREP enzyme activity during the aging, and in the sort of neurodegenerative diseases. And this served as a background to develop small molecule, PREP inhibitors. And this drug development was quite intense, let's say from 90s to 2005.
And for example, our reference compound KYP-2047 was developed by that time. And the idea was that, if we block the enzymatic activity of PREP, we are able to elevate neuropeptide levels in the brain and enhance memory. The idea was good. Preclinical models showed some effect, good enough, that a couple of the PREP inhibitors were tested in the clinical trials. But there there wasn't any effect and looking at back now, getting a memory effect on aged healthy individuals is probably very difficult no matter what you try. But the important part was that PREP inhibition was shown to be safe in phase one and two clinical trials. Three of them were tested KYP-2047 wasn't one of them
but they would turn not to be safe. But when the clinical trials failed, of course the interest in PREP slightly decreased. Until 2008, a group from Belgium, they showed that PREP can enhance the aggregation of alpha-synuclein which is, basically, very easy to get in an in vitro setting, what happened here. But important was that by using PREP inhibitors, they were able to block this effect. And why this alpha-synuclien is then again so important? So alpha-synuclein is one of the main components of Lewy bodies that are then again used as a hallmark for Parkinson's disease and a couple of other diseases called synucleinopathies. So, the alpha-synuclein, when it finally forms the Lewy body, it's in this very tightly aggregated form.
And recent studies have shown that it's, actually, something that happens in between. This, when alpha-synuclein starts to aggregate and before it forms a Lewy body, that's toxic for the cells. And that's something we've been able to target interpret inhibitors. So there's
about 10 years of science behind this, and this 15 minutes is not enough to go through that. But what we noticed is that PREP makes a direct interaction with alpha-synuclein. It enhances its aggregation and it also regulates autophagy, which is kind of a cellular recycle center that, then again, decrease these synuclein oligomers aggregates and other toxic species. And both of these are not related with with this enzymatic effects of PREP. But it's a protein protein interaction. And in the best case, what we've been able to do in the animal studies, we showed that when we give an animal an overdose of alpha-synuclein by using virus vector, it starts to generate behavioral deficit. And when we start the treatment when there is already a behavioral deficit, we are able to
reduce, or actually, almost completely remove this behavioral problem, and reduce the synuclein oligomers. And of course, this was very nice finding but, then again, we started to think, that well maybe we need to now do something else with the PREP inhibitors. And that's when we actually started to plan and apply this Business Finland project.s because these former prep inhibitors, like KYP-2047, they are very very widely patented, like in the old days, and then there are even some new buttons. Where they cover, usually a lot of neurodegenerative diseases. The other thing, what we found in our assays that this ic50 that we used to show that how effective these PREP compounds, PREP inhibitors are to inhibit the enzymatic activity of PREP.
It doesn't correlate with, for example, synuclien aggregation or autophagy induction. There were some very important PREP inhibitors that didn't do anything and then some, that were considered not potent at all in the micromolar range, and they were actually quite effective. And this served as an idea for us to start developing new replicants and initiate this project. And during this neuroPREP, Business Finland project, we have developed five different series of new PREP inhibitors, or I would say PREP ligands. And as you can see, this red arrow is the KYP-2047. And for example, HUP-46, this blue arrow, they are way more effective in synuclein aggregation or to block synuclein aggregation and the induced autophagy. And we've been doing this cellular screenings and, eventually, progressed to the animal models with this. And it was quite interesting to
see, that when we used, or basically repeated this virus vector study, that I showed earlier, but they used a alpha-synuclein vector, that was more toxic than the one we used earlier. KYP-2047 couldn't anymore block the behavior deficit but our new compound HUP-46 was able to do it. And it turned out to be a bit more effective, or reducing synuclein, and it solved both of them, showed some neural protection but it appeared that HUP-46 was a bit more effective. Also on this one we are still under the studies. So therefore, these are quite preliminary still, but it seems that these new compounds, that
were pretty good in the cell models, they were, also, effective in the animal models. And I was speaking about Alzheimer's disease as well at the topic, though, I didn't show any data about that. Hopefully, we have pretty soon, I hope it will be as a Christmas present for me, that we get the good results from the Alzheimer mouse model, but so far there isn't any results from that. But, we have to remember that there are several common toxic mechanisms in among the neurodegenerative diseases, for example, cellular stress, neuronal over activity cell to cell spreading and this toxic protein accumulation.
And we know, that with PREP inhibitor we can target on several of those and that's why we think that the PREP inhibitors can be applicable for several neurodegenerative diseases. We do have some data on on the Alzheimer's cellular models but I didn't present them at this time. So that's why we kind of think, that our approach, this multi-targeting approach, might be successful in term, if you compare it to the former approach, where you target generally on one toxic mechanism at the time Okay, that's all I had to say about this. Of course, acknowledgements, there is a lot of science behind this, before even the scenario project and i'm happy to answer your questions. Thank you very much Timo for a great presentation. And now, let me introduce our next speaker
who is an enthusiastic innovator and researcher with entrepreneurial mindset Marko Havu, who will tell us about MEG-MRI projects at Aalto University. Marco is doctoral candidate in MEG-MRI research group at the department of Neuroscience and Biomedical Engineering in Aalto University. and thanks Marko for coming, now screen is yours! Thank you Dovile. Right, like Dovile said I'm from
the MEG-MRI research group at Aalto University. And I'll first tell a bit about the project and then move on, to challenges and experiences, that we've gained during the project. And also what makes this successful commercialisation projects in neuroscience, in my opinion. The first, worldwide one out of six people suffer from some kind of brain disorder
and in Europe the annual cost for society is over 800 billion euros. Functional brain imaging is a tool used in diagnosis and treatment of many of them. However, today imaging the electrical activity in the brain requires two studies. First, we need functional data that comes from magnetoencephalography or electroencephalography but, in addition to that, we need anatomical or structural data, that usually comes from magnetic resonance imaging. The necessity of two studies, makes this process inaccurate, impractical and costly. So our value proposition is a hybrid brain scanner, that can get both, the functional and the structural data in a single scan.
this improves the workflow and saves a lot of time. It also means, that we can totally eliminate the worst-case, localisation errors, and in addition, our technology enables complete new kinds of brain research. It has, for example, a unique contrast for cancerous brain tissue. The technology has been developed for over a decade, in the the first EU funded project , in MEG-MRI, a scientific proof of concept was built. It had sensors at the back of the head.
Then there was another EU funded project. a FET project, Feature in Emerging Technologies, in a Horizon 2020 program, called BreakBen, and that culminated in a whole head research prototype. So, now we have world's first prototype, which is able to measure whole head at once. Right now, we're further refining the prototype and the clinical validation will start next year. We have two ongoing commercialisation projects, another EU funded project Max Pass is a FET innovation launchpad project and then we have the Business Finland funded TUTLI project. One pattern for the pre-realization method was granted in 2017
and we have two more applications in the PCT phase. The clinical foundation studies that we have planned, include patients with epilepsy, Alzheimer's disease and brain cancer. In the case of epilepsy, we seek to decrease the time it takes for a clinician to analyse the data, and in brain cancer, early detection could save lives.
It's been estimated that spotting Alzheimer's disease early, could save almost 8 trillion US dollars during the lifetime of the current population, in the United States alone. This is our team in the TUTLI project. Koos Zevenhoven, is the research group leader. He's been developing the technology since the beginning, and is the world's top most expert in ultra low- field MRI instrumentation and physics. Professor Risto Ilmoniemi is the head of our department. He's the father of the project. He's had a great track record in in converting groundbreaking research into businesses, he's a pioneer in MEG, transcranial magnetic stimulation, and he also served as the CEO of the Next STIM in the beginning. Thomas Lemström is an expert in strategy and roadmaps, and I'm a product developer
with entrepreneurial background. I joined the project four years ago, while the BreakBen project was ongoing, and it had, I think, started one year before where I started. Brain imaging is one of the fastest growing imaging segments with seven to nine percent growth per year. And we estimate that the immediate market for MEG-MRI will be 150 million
by 2029. In addition, there is potential for another 350 million, if finding support to use in all key application areas. Our competition comes mainly from the existing functional imaging modalities. They all have their shortcomings but they also have a large installed base. Here, you can see comparison of some key metrics between the existing functional imaging modalities and our technology. The unit cost for a scanner will be in the range from 2 million to 4 million euros and we're going to the market in three phases. First, we're going to target research institutes, because that's where
we can immediately bring in value. Also, getting approvals from FDA, CE or the FDA and CE approval, can take time. And then also may require clinical studies, so hospitals will come later. First, the research-oriented university hospitals and once the clinical value is proven, the other hospitals. So that's what I have to say about the the project and then I'll tell a
bit about the experiences we've had with the project, and also SPARK Finland program. So why apply for research to business funding? Well, first of all, I really like the application process. It's it's smooth and it, actually, improves your project because. It's a bit different, from what they use, you you're supposed to first pitch the idea and then, if you get a green light then you can send-in the actual application, or the project plan. So it requires you to think all the impact of your projects and the alternatives for it.
At least in Aalto, I thinking, is in Helsinki University as well, maybe in all universities, the innovation services organized pitching workshop. So, you can prepare for this, and I would, actually, suggest that you start from really really short pitch, say one minute pitch, to really crystallize what's important in the project and then you can add more stuff later on. Second of all, it's full funding in the sense, that you can, it's substantial enough for you to, actually, complete the commercialisation project. Many of these fundings you get are are fairly small so it's not you won't be able to go through a hopeful commercialisation project with that funding only but with this one you can, actually, plan a project that will take you, as far, as to the market, if your field is all right for that. And you're able to get enough funding for that the the amount of funding you get from Business Finland is 70. So, you still need to have some on top of that but the scale is right. We're also SPARKies, so, we're members of the SPARK Finland community. And the number
one reason we joined that, was networking with advisors, investors, potential customers. we joined SPARK, one year ago. And at that point, we were still looking for a startup professional to join the steering group of our TUTLI project and through SPARK Finland we got a great additional member, who not only is a startup professional, but he used to be a country manager for a large med-tech company in Finland. And is familiar with all the problems we face, as a newcomer, trying to to get into a market where these big players are, already have established their position there. And, in addition to this networking,
constant feedback and benchmarking it's a very valuable asset you get from SPARK Finland. And, as an extra, we've also benefited from training, for example in regulatory matters, so for all neuroscience projects that apply for TUTLI funding, I also recommend SPARK Finland. So what can I offer, as a step for success? First let's look at the challenges we've had. First of all, technology in our case, in other cases it might be scientific challenges, but in our case the technology is challenging, mainly because the difference between the smallest signals we're trying to measure and the pre-polarisation pulses we use is 14 orders of magnitude, which is huge in any field of engineering. Also resources, both financial and human. So, financial resources, especially after TUTLI,
like I said, TUTLI funding is substantial so it covers pretty much everything we need at this point. But apart from planning the project, your number one concern during TUTLI survey covering the funding for after TUTLI ends, or Research to Business, as it's called these days. Especially in capital intensive fields, like like ours, or projects, which end with low technology readiness level, it might not be so easy to... Or after the total project you won't be ready to enter the market yet. You still need some additional funding, and even in case you
have some kind of easy, or relatively easy projects, for example an app. You still need some funding for it. Venture capital or whatever it is but you still need to get some funding to get to the market.
One way to succeed is need-based innovation, so you identify a need, and then develop a solution to the underlying problem. But since we're all researchers, then this may not be sort of the path to take. You already have a scientific or technological challenge, that you wish to solve. And that's how our project all also started, combining two inherently incompatible technologies with the challenge, that they wanted to to overcome, and that's been the focus. But since the beginning there has been a focus on the impact, focus on the value and that's what I encourage you to do.
So think about the value and impact. There are tools, like for example, lean canvas, that you can use to to design the value proposition, and I recommend those. There, they also, usually, improve the research project, like I said, in pitching you need to think about the impact and alternatives. And once you go through this process, it usually also gives ideas for for research and,
if nothing else, they improve improve your chances to to get also scientific funding. And as last point, I would like to say, that team is the most important thing in any commercialisation project, so try to get the people you need. People with money, or people who are smarter than you are good members of the team. And a bit short staffed on the engineering side at the moment. So, all that when I saw that
team photo, everyone we got, is in that photo and we would need some more people. So, if you know talented people who would like to join in imaging projects, and i'd be happy to know. Thank you I'll be happy to answer any questions you might have. Thank you Marko, so let's go to our next speaker, Philip Scheperjans, who is inovator and medical doctor. He obtained his medical degree in Düsseldorf University, Germany. He also holds a docent title and focus
on microbial role in Parkinson's disease, and as you may guess, today he will tell us about microbiome-based diagnosis for Parkinson's. So thank you Philip, for giving us a great opportunity to learn about your project! Screen is yours. Okay, thank you very much for the invitation. All right, so my presentation is rather short, because I just want to leave also
enough time for for discussion. So my story is a bit different from that of the previous speakers, in the sense that this project was not, it didn't, was not supported by TUTLI, because it is not related to this stage anymore to the university and, so TUTLI projects are required that that the university has a stake in the project and so in this case for several reasons it's not the case, so in that sense, the the whole process of funding, and then progress is a bit different in this case. So maybe even though Timo already gave a very nice introduction, I also have a few main points about Parkinson's disease. So, Parkinson's disease
is my main focus clinically and also in research. And it's the second most common neurodegenerative disorder, and the main symptoms, as Timo mentioned, is a movement disorder syndrome. So, slowness of movement, muscle stiffness, trauma, and in the advanced stages, also posture instabilities. So problems with balance. And we have about 15 000 in Finland, and so,
Timo mentioned, ten million patients. In my source, it was mentioned five million patients, so probably the truth somewhere in between. So, there's many million patients in in the world and there are several problems related to the treatment of Parkinson's disease. First of all, we diagnose Parkinson's quite late. So, in the stage when the patients exhibit motor symptoms, we know that already about 60% of the dopamine producing nerve cells in the brain have died. We know that this correlates with the motor symptoms and, obviously, in terms of stopping, or slowing down a disease, such as Parkinson's disease, we would like to treat as early, as possible. So we're not very well in picking Parkinson's disease up, currently. And
we don't know what is causing Parkinson's disease, but we know that it is chronically progressing, and that nerve cells progressively die. But we don't know, exactly why this, is the case. And I think, what is the most striking thing about our current treatment of Parkinson's disease, is that the best drug, the most effective drug, that we're using for Parkinson's disease which is named Levodopa, it has been discovered in 1967. So it was before
the first man landed on the moon. And it is still the most effective treatment for Parkinson's disease, and then no really, any major revolutions have happened. In the pharmacological, a non-invasive treatment of Parkinson's disease. We have learned quite a lot in in recent years, about the how and where Parkinson's disease starts. And, especially, it has been recognised that the gut seems to play an important role in Parkinson's disease. Recently we have even seen reports, that there may be
a certain subgroup of Parkinson's patients where the disease, actually, starts in the gut, and not in the brain. But then the pathology would like spread from the gut upwards to the brain stem. And only then we would see the classical motor symptoms. And so, there is quite strong evidence that there is widespread dysfunction in the gut. There is a low-grade inflammation
in the intestines, and that we can also see the alpha-synuclein inclusions, that Timo mentioned, or already in his talk, that we can see the same neuropathological changes, also in the gut. And there's, even though all mechanisms are not known, but we know that that there is neural inflammation going on, which is probably progressively, also (or) is related to the disease progression, mitochondria, just function with oxidative stress. So, that is, I think, also one problem of the whole Parkinson's disease field, is that we still have a lack of understanding how these manufacturers, really interact and contribute. And that is why we get interested in the gut–brain access, and its role in Parkinson's disease. So, just to quickly, get your acquainted with the concept of the gut–brain axis Basically, it means that, we have learned, how much the gut, and in particular gut bacteria, are interacting with the brain. For example, by programming the immune system, but also by directly
affecting the vagus nerve, and also by producing neurotransmitters and other metabolites, such as short-shaped fatty acids, that affect brain function and also structural integrity. And so, our interest is in finding out whether we could develop a completely new way of tackling Parkinson's disease by using the gut–brain axis to influence the pathological process of Parkinson's disease. I did that, in that context, we and all others, that are trying to to develop treatments for Parkinson's disease we're faced with the problem that there is a strong heterogeneity in the symptoms, but probably also in the pathology. Between the mechanisms that are involved in Parkinson's disease, between different patients. And so, at this stage we don't have any tool that we could use to, specifically identify certain subgroups of patients, and could try to develop specific treatments for these subgroups based on their underlying pathology. And I think that one of the main reasons why, so far, all efforts to slow down Parkinson's disease have failed is, that usually these treatments or these drugs are being tested in a group of patients that probably consists of different subgroups, where you could have certain individuals, that have a very strong response to the specific treatment. But you could also have a reasonably
large group, that doesn't respond at all, because they have a different underlying mechanism. And so this, the same, seems to be true also for the involvement of the gut in Parkinson's disease. And so, we desperately need biomarkers that we can use to identify those patients, that are the most suitable for the the treatment. Concept that we would like to test and, so we started, studying the the gut microbiota in Parkinson's disease in 2012. And we were fortunate, in the sense, that we were the first to be able to publish about these findings, and since we were the first, we were also we had the chance to to try to get patents for certain applications or for microbiome analysis, in the diagnosis, or diagnostic process of Parkinson's disease, and also related to certain treatment aspects. So, here I will focus on the diagnostic side of it, and so what we
found, was basically a reduction in the abundance of Prevotella bacteria in the stool of Parkinson's patients, and an increase of of Akkermansia. We also found some other bacteria that were altered but the strongest signal was this contrast between Prevotella and Akkermansia. We were also quite fortunate, because those findings, eventually, turned out to be the best reproduced findings, across different cohorts and continents and ethnic groups to be altered in particular disease. And so it seemed, it was the most robust, the most robust finding as well and, based on literature, and subsequent research, there is some evidence for these bacteria being related to the integrity of the mucus barrier of the gut. So basically, protecting, or protecting the especially Prevotella protecting the gut and the human organism from, for example, toxins and other pro-inflammatory factors, that can be in the gut lumen. And also, they seem to be related to the production of short-chain fatty acids, that also regulate the immune system.
And that may even affect neural inflammation in the brain, and so with respect to the application of potential microbiome, modifying treatments. We think that it is crucial to identify those patients that have the highest chances of benefiting from such a treatment, and it turned out, that what you see on the right side in the graph, is that, actually, when you look at the whole population of participants patients, there is only about 25% of patients that actually have a clear, clearly abnormal microbiome, whereas the rest is, basically, you cannot really discern them from healthy control subjects, in terms of their microbiome. So this again, emphasises my previous point that that we need to find markers to identify such subgroups. And that's what we basically did. So, we took our data from our research and our studies on the underground microbiome repair in this disease, and developed a test platform that allows us with a turnaround of about one to two weeks, to identify from a fecal sample of a Parkinson's patients, whether this patient has an abnormal microbiome in comparison to other Parkinson's patients and health controls. And those would be the the patients you see on the right side, those large black dots, would be those so-called dysbiotic patients. So, that have an abnormal microbiome. and so for the
the concept of using microbiome analysis in the diagnostics of Parkinson's disease we have granted patents in Europe and the US, but we also have undisclosed proprietary algorithms that we use to analyse this data and to perform this testing. And so what we're doing in the next step is, and what we have received funding for us, we will start recruiting, actually, we have started recruiting patients now, so we will conduct a clinical trial in three centers in Finland, where we will recruit our 48 Parkinson's patients and we will use the test that we developed to identify only those patients, that that have a a an abnormal microbiome and so we will restrict the the study to people that have the abnormal microbiome. And when we, in these 48 patients, we will give them a what is called a fecal microbiota transplantation, so essentially, replacing their abnormal microbiome with that of a healthy donor and we will then follow up, the safety of the procedure and the functional efficacy, so how it potentially alleviates Parkinson's symptoms, and will be also a large area of target engagement studies. And so, we hope, that this will help us to to establish this test platform as a an easy and clinically feasible tool to identify a subgroup of Parkinson's patients that is most likely to benefit from microbiome modulation treatment. And yeah, this was actually my my last slide and I'm happy to further discuss on this topic, or to to answer any questions. Thank you very much. Okay, thank you very much Philip! And lastly we will have Kajsa
telling us about Business Finland call. Yes, okay, good afternoon everybody. I'm quite sure, after this inspiring talks by the gentleman, hopefully quite many of you have gotten interested in probably commercialising some of your own ideas, or inventions, this is actually, the perfect timing for that. The Research to Business funding tool has two funding calls annually, and the next one is in March next year (2021), but before getting there, are some critical steps still to pass. And that's why, actually, it is good to activate yourselves now, if you're interested in this funding type. The advices I will be sharing here, are for the University of Helsinki researchers.
They will be sort of detail of the process at University of Helsinki. The application process as you already learned, includes a mandatory sales pitch to Business Finland, that will be about one month before the application deadline. That will be sort of your entrance ticket to the whole application process, because you will need to get the either, a yellow or a green light, from Business Finland, in order to actually even be eligible to apply, or let's say they will encourage you to apply. The innovation units at different universities coordinate these application types, and in addition to the coordination, HIS, Helsinki Innovation Services, which is, essentially, the innovation you need at Helsinki University, also supports the applicants. I'm quite sure that all of you are very experienced in writing grant applications, but I think ,especially, Philip, pointed out that, this requires a bit different mindset, as this is commercialisation funding, and therefore, we have seen that it's valuable to have a short preparation process for this. The preparation process at our university is essentially the so-called NABC training program. The letters come from Need, Approach, Benefit and Competition.
This is the format that Business Finland encourages you to use when pitching and preparing your project plan. So, the training will consist of three afternoon events, in the current state, held via Zoom and then, an internal university training pitch. Also the afternoon sessions will include pitch training, so in addition to the pitch training, we'll offer you project plan and application advice and small hands-on workshops. Business Finland will evaluate certain aspects of your application.
They will be interested in the scalability of your business , the commercial skills in your team, the business model you are planning . So there are certain topics, that probably will benefit from brainstorming and sparring together in these sessions. You're very welcome to register to this NABC training program, latest 18th of December (2020). The link for the application you will find either via the HIS, or the helsinki.fi webpage, and my colleague, also copied the link to the chat box. You can reach us via our webpage, you can email me, you'll also find us on Twitter and LinkedIn. So please, feel free, to be in touch with us, if you have any questions about this
funding type or, if you have questions already now, I'm happy to take them, of course. Thank you!